Clinical characteristics of the 3 patient populations at the time of diagnosis of IPA
| Characteristic . | Allogeneic HSCT (N = 23) . | AL (N = 22) . | Others* (N = 10) . |
|---|---|---|---|
| Female, no. (%) | 8 (35) | 15 (68) | 3 (30) |
| Mean age, y (range) | 37 (10-78) | 53 (16-72) | 64 (45-72) |
| EORTC diagnostic classification, no. (%) | |||
| Proven | 2 (9) | 1 (5) | 1 (10) |
| Probable | 20 (87) | 13 (59) | 10 (90) |
| Possible | 1 (4) | 8 (36) | 0 (0) |
| Clinical presentation, no. (%) | |||
| Fever | 10 (43) | 21 (95) | 8 (80) |
| Cough | 16 (70) | 14 (64) | 7 (70) |
| Expectoration | 9 (39) | 8 (36) | 4 (40) |
| Hemoptysis | 0 (0) | 1 (5) | 1 (10) |
| Mechanical ventilation | 0 (0) | 0 (0) | 3 (30) |
| Concomitant pulmonary infection | 11 (48) | 1 (5) | 4 (40) |
| Bacterial† | 6 | 1 | 3 |
| Viral‡ | 5 | 1 | 0 |
| Fungal§ | 0 | 0 | 1 |
| Receiving corticosteroids | 19 (83) | 5 (23) | 6 (60) |
| Leukocyte count | |||
| < 100/mm3 | 7 (30) | 18 (82) | 2 (20) |
| 100-500/mm3 | 5 (22) | 1 (5) | 3 (30) |
| > 500/mm3 | 11 (48) | 3 (14) | 5 (50) |
| Leukopenia (< 500/mm3) for > 15 consecutive days during last 3 months | 15 (65) | 21 (95) | 4 (40) |
| Anti–mold therapy in the last 15 days‖ | 17 (74) | 16 (73) | 1 (10) |
| Characteristic . | Allogeneic HSCT (N = 23) . | AL (N = 22) . | Others* (N = 10) . |
|---|---|---|---|
| Female, no. (%) | 8 (35) | 15 (68) | 3 (30) |
| Mean age, y (range) | 37 (10-78) | 53 (16-72) | 64 (45-72) |
| EORTC diagnostic classification, no. (%) | |||
| Proven | 2 (9) | 1 (5) | 1 (10) |
| Probable | 20 (87) | 13 (59) | 10 (90) |
| Possible | 1 (4) | 8 (36) | 0 (0) |
| Clinical presentation, no. (%) | |||
| Fever | 10 (43) | 21 (95) | 8 (80) |
| Cough | 16 (70) | 14 (64) | 7 (70) |
| Expectoration | 9 (39) | 8 (36) | 4 (40) |
| Hemoptysis | 0 (0) | 1 (5) | 1 (10) |
| Mechanical ventilation | 0 (0) | 0 (0) | 3 (30) |
| Concomitant pulmonary infection | 11 (48) | 1 (5) | 4 (40) |
| Bacterial† | 6 | 1 | 3 |
| Viral‡ | 5 | 1 | 0 |
| Fungal§ | 0 | 0 | 1 |
| Receiving corticosteroids | 19 (83) | 5 (23) | 6 (60) |
| Leukocyte count | |||
| < 100/mm3 | 7 (30) | 18 (82) | 2 (20) |
| 100-500/mm3 | 5 (22) | 1 (5) | 3 (30) |
| > 500/mm3 | 11 (48) | 3 (14) | 5 (50) |
| Leukopenia (< 500/mm3) for > 15 consecutive days during last 3 months | 15 (65) | 21 (95) | 4 (40) |
| Anti–mold therapy in the last 15 days‖ | 17 (74) | 16 (73) | 1 (10) |
Non-AL patients with no allogeneic HSCT (lymphoma, chronic lymphocytic leukemia, multiple myeloma, myelodysplastic syndrome, hairy cell leukemia).
Pseudomonas aeruginosa, Escherichia coli, Streptococcus oralis, Acinetobacter baumanii, Staphylococcus aureus, Moraxella catarrhalis, and Lactobacillus.
Parainfluenza virus, adenovirus, and respiratory syncytial virus.
Candida albicans.
Empirical treatment, n = 22; prophylaxis, n = 12; caspofungin, n = 23; voriconazole, n = 3; liposomal amphotericin B, n = 6; amphotericin B, n = 2; and other, n = 2.